MAPT and Alzheimer disease: To rule out preclinical Alzheimer’s disease in the neurological control group, only cases with normal CSF levels amyloid-β1–42 (>550 ng/L), total tau (<400 ng/L), and phosphorylated tau (<50 ng/L) were included.